Europe Real Time Polymerase Chain Reaction Market Share, Size, Growth and Segment Forecasts to 2022
- Submitted by: Hexareports
- Views: 67
- Category: Other
- Date Submitted: 08/10/2016 12:21 AM
- Pages: 4
- Report this Essay
Europe Real Time Polymerase Chain Reaction (qPCR) market is expected to reach over USD 395.8 million by 2022, according to a new report by Grand View Research Inc. Technological advancements on the grounds of accuracy, portability, and cost-effectiveness are expected to serve this market as high-impact rendering drivers over the forecast period. For instance, Applied Biosystems has QuantStudio Dx series for rapid and affordable diagnosis of molecular abnormalities at early stage of diseases development.
Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use.
Browse Detail Report With TOC @ http://hexareports.com/report/europe-real-time-polymerase-chain-reaction-qpcr-market/details
Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders.
Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK's MEGA-A3 cancer immunotherapy.
Emerging opportunities for both companies for development of products pertaining to early detection of diseases such as cancer and infectious diseases are estimated to enhance such collaborative activities over the forecast period.
Further key findings from the study suggest:
Thermo Fisher/ABI dominated the market with a revenue share of over 38% in 2014 owing to high installed base of instruments such as StepOne, 7500, ViiA 7, and...
Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use.
Browse Detail Report With TOC @ http://hexareports.com/report/europe-real-time-polymerase-chain-reaction-qpcr-market/details
Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders.
Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK's MEGA-A3 cancer immunotherapy.
Emerging opportunities for both companies for development of products pertaining to early detection of diseases such as cancer and infectious diseases are estimated to enhance such collaborative activities over the forecast period.
Further key findings from the study suggest:
Thermo Fisher/ABI dominated the market with a revenue share of over 38% in 2014 owing to high installed base of instruments such as StepOne, 7500, ViiA 7, and...